Altogether, these results provided evidence that USP22 promotes the proliferation of hepatocellular carcinoma cells by stabilising CKD11B and increases Sorafenib resistance through reducing H2BK120ub level and TFRC transcription in vivo. The gene discussed is TFRC; the disease is hepatocellular carcinoma.